https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-728
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-7282018-10-29 00:00:002018-10-29 00:00:00Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-200
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-2002018-10-25 00:00:002018-10-25 00:00:00Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-22 / Cytotherapy 2018 Nov;20(11):1309-1323
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-22 / Cytotherapy 2018 Nov;20(11):1309-13232018-10-22 00:00:002019-04-03 09:49:17Empowering dendritic cell cancer vaccination: the role of combinatorial strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
root
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
root2018-10-21 21:23:242019-07-15 12:39:50Nobelpreis für Medizin 2018 für die Entwicklung neuer Krebstherapien mit Checkpoint Inhibitoren
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-17 / 2018 Oct;10(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-17 / 2018 Oct;10(10)2018-10-17 00:00:002018-10-17 00:00:00Immune Function and Micronutrient Requirements Change over the Life Course
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-4062018-10-12 00:00:002019-03-25 10:39:48Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-11 / Exp Ther Med 2018 Dec;16(6):5123-5129
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-11 / Exp Ther Med 2018 Dec;16(6):5123-51292018-10-11 00:00:002018-10-11 00:00:00Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-10 / Cancer Immunol. Immunother. 2019 Jan;68(1):121-130
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-10 / Cancer Immunol. Immunother. 2019 Jan;68(1):121-1302018-10-10 00:00:002019-03-25 10:37:19Phase I/II clinical trial of a Wilms‘ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-08 / 2018 10;46(5):1147-1159
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-08 / 2018 10;46(5):1147-11592018-10-08 00:00:002018-10-08 00:00:00Vitamin C and immune cell function in inflammation and cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-6702018-10-01 00:00:002018-10-01 00:00:00Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
